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ABSTRACT: Increasing bacterial resistance against current antibiotics and lack of new molecules to combat bacterial resistance
are key challenges to global health. There is, therefore, a continuing need to develop new antibiotics. Teixobactin, a cyclic
undecapeptide, displays excellent antibacterial activities against a range of pathogenic bacteria, such as methicillin-resistant
Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis. Interestingly, it operates by multiple modes of actions and is
bactericidal toward S. aureus without detectable resistance. This unique combination of wide Gram-positive activity coupled with
its inability to elicit resistance make teixobactin a very attractive molecule for antimicrobial therapeutic development. This
Viewpoint discusses teixobactin, its analogues, and the challenges and opportunities associated with their future development.
By 2050, antimicrobial resistance (AMR) is predicted to beresponsible for more deaths than cancer.1 There is an
extremely high demand for new antibiotics with novel modes of
action to combat the rampant spread of resistance encumbering
classic therapeutic agents. One such recently discovered
molecule is teixobactin,2 which has shown excellent activity
against a range of clinically relevant, Gram-positive pathogens
including methicillin-resistant Staphylococcus aureus (MRSA),
Mycobacterium tuberculosis, and Enterococcus spp. (vancomycin-
resistant enterococci, VRE).
Teixobactin was isolated from a new species of previously
uncultured Gram-negative bacteria provisionally named Elef -
theria terrae via use of iChip culturing technology.2 Teixobactin
is a cyclic undecapeptide comprised of four D-amino acids,
namely, N-Me-D-Phe1, D-Gln4, D-allo-Ile5, and D-Thr8, and an
unusual L-allo-enduracididine amino acid (Figure 1A). The
putative biosynthetic cluster for this depsipeptide natural
product consists of two large (∼697 kDa) nonribosomal petide
synthetases (NRPSs) Txo1 and Txo2. The latter enzyme, Txo2,
contains two consecutive thioesterase domains on the terminal
module, a rare feature within NRPSs. The producing bacteria
export teixobactin across their outer membrane where it exerts
antimicrobial action against potentially competitive organisms.
There have been no other protective resistance mechanisms
reported in E. terrae against teixobactin, implying that resistance
through horizontal gene transfer from the producing organism
is improbable.2
The bactericidal activity of teixobactin against S. aureus is
superior to vancomycin, and it retains excellent bactericidal
activity against vancomycin-intermediate resistant S. aureus
(VISA). Teixobactin is not eﬀective against Gram negative
bacteria, most likely due to the outer membrane barrier, as
evidenced by the fact that teixobactin showed good activity
against the outer membrane deﬁcient strain Escherichia coli
asmB1.2 Most interestingly, no resistant mutants have emerged
from S. aureus and grown under subminimum inhibitory
concentrations (MIC). This absence of any detectable resistant
mutants after serial passaging makes teixobactin a particularly
attractive molecule for drug development and is suggestive of a
nonprotein drug target. Treatment of S. aureus with teixobactin
resulted in accumulation of undecaprenyl-N-acetylmuramic acid
pentapeptide (UDP-MurNAc-peptide), a precursor of the cell-
wall peptidoglycan.2 A similar observation was made in bacteria
treated with vancomycin; however, while both teixobactin and
vancomycin bind to lipid II, teixobactin’s antibacterial activity
against E. faecalis and E. faecium (VRE) suggests teixobactin
binding to lipid II does not involve the peptide stem of lipid II,
a distinguishing feature between these bacterial species.
Detailed in vitro studies have revealed that teixobactin
operates through at least two distinct modes of action.2
Teixobactin binds to precursors (lipid II, precursor for
peptidoglycan biosynthesis, and lipid III, precursor for wall
teichoic acid biosynthesis) (Figure 1C,D) of multiple cell wall
biosynthetic pathways and inhibits the recycling of undecap-
renyl pyrophosphate (C55-PP), which is essential for lipid II and
lipid III biosynthesis. Lipid II is a readily accessible, validated
target for antibiotics such as vancomycin. Only a limited
amount of lipid II can be synthesized at a time by the bacteria
through the lipid II biosynthetic cycle4 which is the key
limitation in bacterial cell wall synthesis, making lipid II a very
desirable target for antibiotic development. By binding to and
trapping discrete, late-stage cell wall intermediates instead of
protein targets, teixobactin curtails genetic alteration of its drug
target in pathogenic bacteria, a common mechanism of
antimicrobial resistance.2
The excellent bactericidal activity of teixobactin is reported
to be due to not only inhibition of peptidoglycan synthesis but
also the synergistic inhibition of wall teichoic acid synthesis.3
The binding of teixobactin to lipid III, a key building block in
the synthesis of wall teichoic acid, reduces the binding of
autolysins (lytic enzymes) resulting in cleavage of intact
peptidoglycan and cell death.3
Binding studies of teixobactin on puriﬁed cell wall precursors
revealed that the antibiotic binds in 2:1 (teixobactin/lipid)
molar ratio with lipid I, lipid II, lipid II (D-lac), lipid III, and
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undecaprenyl pyrophosphate.2 The pyrophosphate moiety and
the ﬁrst sugar moiety (either N-acetylmuramic acid or N-
acetylglucosamine) were originally reported to play important
roles in binding of teixobactin to most of these precursors. We
previously reported the binding of teixobactin analogues
(Figure 1B) to lipid II and the simpliﬁed geranyl
pyrophosphate.5 The minimal binding motif for teixobactin
and its analogues is likely the pyrophosphate moiety and the
polyprenyl chain, which is common in all these cell wall
building blocks. This binding element is highly conserved in
Gram-positive bacterial cell wall biosynthesis. The distinct
mode of binding of teixobactin is responsible for its potent
activity against vancomycin resistant bacteria, capable of solely
mutating the peptidyl portion of lipid II.
Teixobactin showed good serum and microsomal stability
and low cytotoxicity in vitro. Teixobactin is eﬃcacious in vivo,
displaying antibacterial activity in three mouse models of
infection (the protective dose (PD50) of teixobactin in mouse
septicemia model was 0.2 mg/kg). While these results are
encouraging, there remains a signiﬁcant amount of work to be
done to develop teixobactin as an antimicrobial therapeutic
agent for human use. There is a pressing need for analogs of the
original natural product to address common development
issues such as potential oﬀ-target toxicity and metabolic
liabilities in humans. Additionally, teixobactin’s utility is limited
by its low bioavailability, necessitating intravenous delivery.
Access to analogs that may potentially resolve these issues is
precluded by the lengthy and daunting synthesis of the
teixobactin scaﬀold, highlighting the need for novel simpliﬁed
molecules based on the natural product.
Teixobactin research has gained signiﬁcant interest in the
past year with several accounts being published describing the
total synthesis of teixobactin8,9 and its analogues.6,7,10
Currently, there is no ideal synthetic route for teixobactin
and its analogs, which contain the unusual amino acid L-allo-
enduracididine. This amino acid is reported to be important for
the potent antibacterial activity of teixobactin; however, it also
represents a bottleneck in the development of teixobactin
analogues due to various challenges pertaining to this residue’s
synthesis.8 Several research groups, including our own, recently
reported the synthesis of simpliﬁed teixobactin analogues in
which the L-allo-enduracididine is replaced with structurally
similar building blocks such as L-arginine and L-lysine.
Encouragingly, these novel analogues possess a similar
antimicrobial proﬁle to teixobactin against S. aureus but can
be accessed through a greatly simpliﬁed synthetic route from
commercially available precursors.6,7,10
To develop highly potent derivatives of teixobactin, it was
important to gain an understanding of the structure−activity
relationship (SAR) of the nonribosomal peptide’s interaction
with its lipid targets. To this end, we reported the total
syntheses and biological evaluation of the D and L analogues of
Arg10-teixobactin.
5 We successfully deﬁned the three-dimen-
sional molecular structure of seven teixobactin analogues (as
determined via NMR) and reported that the disordered
structure of teixobactin analogues is vital for their biological
activity. The direct 3D structural comparison of two important
Figure 1. (A) Structure of teixobactin2 and its analogue. (B) Arg10-teixobactin.
6,7 Molecular targets of teixobactin, the bacterial cell wall precursor.
(C) Lipid II2 and wall teichoic acid precursor. (D) Lipid III.2
Figure 2. (A) Structure of Arg10-teixobactin exhibiting native stereochemistry. (B) Structure of Arg10-teixobactin comprised of only L-amino acids.
5
(C, D) X-ray crystallographic structure of Ac-Δ1−5-Arg10-teixobactin as the hydrochloride salt showing the top and side views, respectively.
11 Images
reproduced with permission from refs 5 and 11. Copyright 2017 The Royal Society of Chemistry.
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derivatives, namely, Arg10-teixobactin (Figure 2A) and Arg10-
teixobactin, with all L-amino acids (Figure 2B) revealed that
only the former is disordered in its Arg10 and N-terminus and
therefore active whereas the later forms a hairpin structure and
folding onto itself, which presumably precludes cell wall
intermediate binding. The amino acid conﬁgurations of the
four D-amino acids (D-N-Me-Phe1, D-Gln4, D-allo-Ile5, and D-
Thr8) are critical for biological activity, and inverting their
conﬁguration from D to L leads to a signiﬁcant loss in
antibacterial activity. Among the individual amino acids, D-Gln4
is essential and D-allo-Ile5 is important to maintain the
disordered structure. Very recently, Nowick and co-workers
reported the X-ray crystallographic structure of a truncated
teixobactin analogue11 (Figure 2C,D) in which the hydro-
phobic as well as the hydrogen bonding interactions present in
the cavity structure containing a chloride ion were shown.
Interestingly, the arginine residue of this truncated analogue
provides a key interaction with the chloride ion via a folded
conformation in the crystal structure (Figure 2D). Access to
this conformation may only be granted through analogs with
conformational ﬂexibility, as shown in our NMR analysis (vida
supra, Figure 2A). On the basis of the crystal structure, it has
also been hypothesized that the core ring structure of
teixobactin could encompass an anionic molecule such as a
pyrophosphate, but stronger evidence of this has yet to be
reported.
Nowick and co-workers10 reported that any modiﬁcation of
conﬁguration of the residues in the core ring structure of
teixobactin results in a signiﬁcant attenuation in biological
activity. While pursuing the synthesis and development
teixobactin analogues, the Albericio group performed a lysine
scan of Arg10-teixobactin.
12 They revealed that all four
isoleucine residues in teixobactin are critical for biological
activity. However, the L-Ser3, D-Gln4, and Ala9 residues can be
substituted with the corresponding enantiomer of lysine, and
these analogues have comparable biological activity to that of
Arg10-teixobactin.
A thorough model for teixobactin activity and potential
mechanisms of resistance is still in its infancy. An under-
standing of discrete lipid II interactions with teixobactin and its
analogues at the molecular level is currently lacking, and more
structural information will be crucial for the rational design of
more potent analogues of teixobactin. The preliminary
resistance studies of teixobactin against S. aureus and M. tuber-
culosis have indeed been very promising.2 However, there is a
need for rigorous resistance screening against teixobactin in
diﬀerent pathogens such as MRSA and VRE, which are already
resistant to many antibiotics. One might argue that soil bacteria,
which live close to teixobactin producer E. terrae, are most
likely to have already acquired resistance to teixobactin and,
thus, could potentially transfer their resistance by horizontal
transmission. These mechanisms of resistance could arise
through expression of teixobactin modifying enzymes or
mutations that limit the access of teixobactin to lipid II by
thickening the outer cell wall (such as those seen providing
resistance against lantibiotics).
Although teixobactin biology and chemistry have made
signiﬁcant progress in the two years since the molecule’s
discovery, much remains unknown and unexplored. Questions
still persist about the exact mechanism of cell wall intermediate
sequestration, such as: Where in the microbial cell does this
occur? And, why is a 2:1 ratio favoring teixobactin over lipid
optimal? Additionally, several barriers to wide clinical use still
exist, including: a lack of both oral bioavailability and activity
against Gram-negative bacteria. Finally, the ability to predict
resistance mechanisms before clinical testing would prove
essential in the successful, controlled use of this powerful
antibiotic. In this regard, exploring the strategies for teixobactin
resistance in soil microbes and in clinically relevant bacterial
strains (MRSA, VRE) would provide vital clues into potential
resistance liabilities in the future. Through the careful analysis
of teixobactin via new analogs, focused chemical−biology
approaches, and rigorous resistance studies, there is hope that
teixobactin can be translated to lessons and rewards for future
antibiotic drug therapy.
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